Ripertamab

瑞帕妥单抗

Report date: 2023/02/01 17:04:53

Base Information

Drug NameRipertamab
Drug Alias Name重组嵌合抗CD20单克隆抗体（神州细胞工程）Rituximab (Sinocelltech)利妥昔单抗（神州细胞工程）利妥昔单抗生物仿制药（神州细胞工程）利妥昔单抗生物类似药（神州细胞工程） +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsCentral Nervous System LymphomaLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[4] 
Global Approved IndicationsLymphoma, Large B-Cell, Diffuse
Approved Indications in ChinaLymphoma, Large B-Cell, Diffuse
Original Approved Country/TerritoryMainland China
Original Approved Date2022/08/23
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSinoCelltech Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSinoCelltech Ltd
Inactive CompaniesPeking University
Active IndicationsLymphoma, Large B-Cell, Diffuse
Inactive IndicationsCentral Nervous System LymphomaLymphoma, B-CellLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A